Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Arrhythmias

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    August 2022
  1. GRECO LV, Migirov A, Ojamaa K, Li Y, et al
    Stabilizing Cardiac Ryanodine Receptor with Dantrolene Treatment Prevents Binge Alcohol Enhanced Atrial Fibrillation in Rats.
    J Cardiovasc Pharmacol. 2022 Aug 9. pii: 00005344-990000000-00090.
    PubMed     Abstract available


  2. TUNCTAN B, Senol SP, Temiz-Resitoglu M, Yilmaz DE, et al
    Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
    J Cardiovasc Pharmacol. 2022;80:276-293.
    PubMed     Abstract available


    July 2022
  3. TSAGKARIS C, Papazoglou AS, Kartas A, Samaras A, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Jul 29. pii: 00005344-990000000-00089.
    PubMed     Abstract available


    June 2022
  4. CHEN Y, Zhu M, Wang K, Xu Q, et al
    Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombus: An Updated Meta-Analysis of Cohort Studies and Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022;79:935-940.
    PubMed     Abstract available


    May 2022
  5. CARNEVALE R, Biondi-Zoccai G, Giordano A, Pastori D, et al
    From the dining room to the atrium: can we modulate atrial fibrillation risk with micronutrients?
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00057.
    PubMed    


  6. OLIVERI F, Bongiorno A, Compagnoni S, Fasolino A, et al
    Statin and Post-Cardiac Surgery Atrial Fibrillation Prevention: Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 May 11. pii: 00005344-990000000-00049.
    PubMed     Abstract available


  7. PETERSEN J, Castro L, Bengaard AKP, Pecha S, et al
    Muscarinic Receptor Activation Reduces Force and Arrhythmias in Human Atria Independent of IK,ACh.
    J Cardiovasc Pharmacol. 2022;79:678-686.
    PubMed     Abstract available


    April 2022
  8. RUSSO V, Ammendola E, Gasperetti A, Bottino R, et al
    Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    J Cardiovasc Pharmacol. 2022;79:472-478.
    PubMed     Abstract available


    March 2022
  9. HUANG J
    Circulating concentrations of nutrition-related factors are not causally associated with atrial fibrillation: a Mendelian randomization study.
    J Cardiovasc Pharmacol. 2022 Mar 25. pii: 00005344-990000000-00012.
    PubMed     Abstract available


    February 2022
  10. LAM JC, Stevenson B, Lee YG, Maurer J, et al
    Intravenous to oral transition of amiodarone (IOTA): effect of various durations of overlap on atrial fibrillation recurrence post cardiothoracic surgery.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98047.
    PubMed     Abstract available


    January 2022
  11. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    PubMed     Abstract available


    December 2021
  12. WANG Z, Wang W, Li H, Zhang A, et al
    Ivabradine and Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98065.
    PubMed     Abstract available


  13. LI W, Chen X, Xie X, Xu M, et al
    Comparison of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomised controlled trials.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98087.
    PubMed     Abstract available


  14. WANG W, Liu J, Ye H, Wang M, et al
    Effect of Dexmedetomidine on Tachyarrhythmias after Cardiac Surgery: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98086.
    PubMed     Abstract available


    November 2021
  15. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    PubMed     Abstract available


  16. BURASHNIKOV A
    Atrial fibrillation induced by anticancer drugs and underling mechanisms.
    J Cardiovasc Pharmacol. 2021 Nov 17. pii: 00005344-900000000-98110.
    PubMed     Abstract available


  17. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    PubMed     Abstract available


    October 2021
  18. LO CT, Niu F, Fredriks DA, Hui RL, et al
    Evaluation of the effectiveness and safety of Direct Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation who are not Candidates for Warfarin in real world setting.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98121.
    PubMed     Abstract available


    August 2021

  19. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience: Erratum.
    J Cardiovasc Pharmacol. 2021;78:330.
    PubMed    


  20. ZHANG M, Wang H, Bie M, Wang X, et al
    Caveolin-1 Deficiency Induces Atrial Fibrosis and Increases Susceptibility to Atrial Fibrillation by the STAT3 Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:175-183.
    PubMed     Abstract available


    July 2021
  21. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
    Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
    J Cardiovasc Pharmacol. 2021;78:e55-e64.
    PubMed     Abstract available


    June 2021
  22. CHARAFEDDINE K, Zakka P, Dargham BB, Abdulhai F, et al
    Potential Biomarkers in Atrial Fibrillation: Insight into their Clinical Significance.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98188.
    PubMed     Abstract available


  23. SKORNOVA I, Samos M, Bolek T, Kamenistakova A, et al
    Direct oral anticoagulants plasma levels in atrial fibrillation patients at the time of bleeding: a pilot prospective study.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98186.
    PubMed     Abstract available


  24. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    PubMed     Abstract available


    April 2021
  25. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    PubMed     Abstract available


    March 2021
  26. HEIDEMANN J, Tanislav C, Kostev K
    (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients with Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98230.
    PubMed     Abstract available


  27. HORTIGON-VINAGRE MP, Zamora V, Burton FL, Smith GL, et al
    The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    J Cardiovasc Pharmacol. 2021;77:280-290.
    PubMed     Abstract available


    February 2021
  28. ANOUASSI Z, Atallah B, Alsoud LO, El Nekidy W, et al
    Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region.
    J Cardiovasc Pharmacol. 2021;77:182-188.
    PubMed     Abstract available


    December 2020
  29. CORDERO A, Ferreiro JL, Bertomeu-Gonzalez V, Rodriguez-Manero M, et al
    Direct oral anticoagulants vs. vitamin K antagonist after percutaneous coronary interventions in patients with atrial fibrillation: a metanalysis of cardiac ischemic events.
    J Cardiovasc Pharmacol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  30. HELENIAK Z, Papuga-Szela E, Krzysztof P, Anetta U, et al
    Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    J Cardiovasc Pharmacol. 2020;76:671-677.
    PubMed     Abstract available


    November 2020
  31. RIGOPOULOS AG, Kalogeropoulos AS, Tsoporis JN, Sakadakis EA, et al
    Heat shock protein 70 is associated with cardioversion outcome and recurrence of symptomatic recent onset atrial fibrillation in hypertensive patients.
    J Cardiovasc Pharmacol. 2020 Nov 24. doi: 10.1097/FJC.0000000000000962.
    PubMed     Abstract available


  32. NORDBECK P, Hu K
    The trend is your friend: DOACs as standard anticoagulants for patients with atrial fibrillation undergoing percutaneous coronary interventions.
    J Cardiovasc Pharmacol. 2020 Nov 3. doi: 10.1097/FJC.0000000000000950.
    PubMed    


  33. BURASHNIKOV A
    Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
    J Cardiovasc Pharmacol. 2020;76:492-505.
    PubMed     Abstract available


    October 2020
  34. HENRY M, Wosnitza M, Thate-Waschke IM, Bauersachs R, et al
    A Country-Based Comparison of Atrial Fibrillation Patient Preferences for Oral Anticoagulation: An Evaluation of Discrete Choice Experiments in five different Countries.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000936.
    PubMed     Abstract available


  35. LEE ZX, Ang E, Lim XT, Arain SJ, et al
    Association of Risk of Dementia with Direct Oral Anticoagulants versus Warfarin use in Patients with Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000925.
    PubMed     Abstract available


  36. PATTI G, Haas S
    Non-vitamin K antagonist oral anticoagulants and factors influencing the ischaemic and bleeding risk in elderly patients with atrial fibrillation: a review of current evidence.
    J Cardiovasc Pharmacol. 2020 Oct 9. doi: 10.1097/FJC.0000000000000927.
    PubMed     Abstract available


    August 2020
  37. NORDBECK P, Hu K
    Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19.
    J Cardiovasc Pharmacol. 2020;76:123-124.
    PubMed    


    July 2020
  38. CHU Y, Yang Q, Ren L, Yu S, et al
    Late sodium current in atrial cardiomyocytes contributes to the induced and spontaneous atrial fibrillation in rabbit hearts.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000883.
    PubMed     Abstract available


  39. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available


    May 2020
  40. BURASHNIKOV A, Barajas-Martinez H, Hu D, Robinson VM, et al
    The SK Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation via Atrial-selective Inhibition of Sodium Channel Activity.
    J Cardiovasc Pharmacol. 2020 May 20. doi: 10.1097/FJC.0000000000000855.
    PubMed     Abstract available


  41. RUSSO V, Rago A, Carbone A, Bottino R, et al
    Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications.
    J Cardiovasc Pharmacol. 2020 May 18. doi: 10.1097/FJC.0000000000000854.
    PubMed     Abstract available


    March 2020
  42. MA W, Guo X, Wang Q, Sun G, et al
    Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2020 Mar 26. doi: 10.1097/FJC.0000000000000832.
    PubMed     Abstract available


    January 2020
  43. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available


  44. HENDRICKS AK, Nei SD, Greason KL, Scott RA, et al
    Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series.
    J Cardiovasc Pharmacol. 2020;75:41-44.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: